Results of Annual General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held an Annual General Meeting of Members at the offices of BDO Australia, Level 25, 35 Collins Street, Melbourne VIC 3000.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement was authorised for release by Alessandra Gauvin, Company Secretary.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Results of Meeting

Neurotech International Limited

Annual General Meeting

Thursday, 05 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	244,012,742 85.67%	1,150,627 0.40%	8,556,049	39,664,944 13.93%	297,763,690 99.62%	1,150,627 0.38%	8,556,049	-
2 ELECTION OF ANDREW CHAPMAN	P	276,883,089 87.37%	366,056 0.12%	0	39,675,853 12.52%	325,509,356 99.89%	366,056 0.11%	8,707,018	Carried
3 RE-ELECTION OF GERALD QUIGLEY	P	275,428,871 86.91%	1,991,056 0.63%	0	39,505,071 12.47%	329,019,946 99.40%	1,991,056 0.60%	3,571,428	Carried
4 APPROVAL OF 7.1A MANDATE	P	267,395,865 86.69%	1,366,433 0.44%	8,486,847	39,675,853 12.86%	324,729,150 99.58%	1,366,433 0.42%	8,486,847	Carried
5 RATIFICATION OF PRIOR ISSUE OF SHARES UNDER PLACEMENT – LISTING RULE 7.1	P	45,768,003 52.07%	2,461,056 2.80%	7,061,847	39,675,853 45.13%	95,294,270 97.48%	2,461,056 2.52%	7,061,847	Carried
6 RATIFICATION OF PRIOR ISSUE OF SHARES UNDER PLACEMENT – LISTING RULE 7.1A	P	46,034,059 52.37%	2,195,000 2.50%	7,061,847	39,675,853 45.13%	95,560,326 97.75%	2,195,000 2.25%	7,061,847	Carried
7 APPROVAL TO ISSUE SHARES UNDER PLACEMENT	P	242,738,815 85.30%	2,106,627 0.74%	7,015,000	39,737,700 13.96%	300,133,947 99.30%	2,106,627 0.70%	7,015,000	Carried
8 APPROVAL TO ISSUE OPTIONS TO TAYLOR COLLISON	P	259,634,063 85.43%	4,538,235 1.49%	7,015,000	39,737,700 13.08%	317,029,195 98.59%	4,538,235 1.41%	7,015,000	Carried
9 RATIFICATION OF PRIOR ISSUE OF OPTIONS TO CANARY CAPITAL	P	241,743,834 84.94%	3,116,608 1.10%	7,000,000	39,737,700 13.96%	299,138,966 98.97%	3,116,608 1.03%	7,000,000	Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 APPROVAL TO ISSUE OPTIONS TO CANARY CAPITAL	P	171,603,636 80.01%	3,128,235 1.46%	77,128,571	39,737,700 18.53%	228,998,768 98.65%	3,128,235 1.35%	77,128,571	Carried